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Abstract
Problem Pregnancy-associated immunologic alterations
may improve the course of asthma. Severe maternal asthma
with an exacerbation impairs fetal growth.
Method of study Lymphocyte activation was estimated by
ﬂow cytometry analysis of surface markers in non-pregnant
healthy and mild or moderate persistent asthmatic women
and healthy as well as mild or moderate persistent asth-
matic, third trimester pregnant women.
Results Compared with non-pregnant healthy subjects
(n = 12) activated pools within CD4 and CD8 T cells were
larger and the number of NK T cells were increased both in
non-pregnant asthmatic (n = 12) and in healthy pregnant
(n = 13) subjects (all p\0.05). No further lymphocyte
activation was observed in pregnant asthmatics (n = 21)
compared either with non-pregnant asthmatic, or pregnant
healthy women. Average birth weight of newborns was
lower (p\0.05) in the asthmatic than in the healthy
pregnant group.
Conclusion Pregnancy is a state of wide-spread lym-
phocyte activation but it may blunt lymphocyte activation
which characterizes bronchial asthma.
Keywords Asthma  Flow cytometry 
Immunotolerance  Lymphocyte activation  Pregnancy
Abbreviations
BMI Body mass index
FEV1 Forced expiratory volume in 1-s
GINA Global initiative for asthma
PEF Peak expiratory ﬂow
pCO2 Partial pressure of carbon-dioxide in arterialized
capillary blood
pO2 Partial pressure of oxygen in arterialized capillary
blood
Raw Airway resistance
Introduction
Extrinsic bronchial asthma is induced by allergic airway
inﬂammation, where allergen activated T and B lympho-
cytes play important pathogenetic roles [1]. Lymphocyte
activation in asthma is reﬂected by increased subpopula-
tions that express various activation markers on the
cell surface. Once a lymphocyte becomes activated certain
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on the membrane, for example the major histocompatibility
complex antigen HLA-DR [2–4], the apoptosis inducing
domain Fas (CD95, [5]), the interleukin-2 (IL-2) receptor
(CD25, [2–4]), the co-stimulatory molecule CD28 [6], and
adhesion molecules such as intercellular adhesion mole-
cule-1 (ICAM-1, CD54, [7]). Other integrins including
Mac-1 (CD11b) and the transferrin receptor (CD71) are
also expressed on both the surface of T and B cells upon
activation [8]. The intensity of lymphocyte activation
correlates with the severity of airway symptoms in asth-
matic patients [2, 4, 9, 10].
More women than men suffer from asthma [11] and the
natural course of asthma is frequently modiﬁed by preg-
nancy [12]. In about one-third of pregnant asthmatics
respiratory symptoms improve, in another third symptoms
remain unchanged, and in the remaining third asthma
worsens during pregnancy [13]. The cause of this vari-
ability is unknown and may be mostly immunologic in
nature [14]. Pregnancy is known to interfere with the nat-
ural course of immunologic diseases such as rheumatoid
arthritis [15, 16], or autoimmune thyroiditis [17]. Symp-
toms of these autoimmune diseases improve or remission
may even occur during pregnancy before postpartum
relapse.
Previous studies on T cell numbers and function during
normal pregnancy reveal deﬁnite signs of both activation
and hyporesponsiveness (anergy, clonal deletion) [18].
Ku ¨hnert et al. [19] and Mahmoud et al. [20–22] demon-
strated signiﬁcantly increased numbers of surface HLA-
DR
?, CD25
? and CD54
? CD4 and CD8 lymphocytes in
peripheral blood of healthy pregnant women. Other authors
[23, 24] also reported higher fractions of CD54
? and
CD11b
? CD4 and CD8 lymphocytes in peripheral blood
and also in decidua, where activated lymphocytes may play
essential roles in the maintenance of placental growth and
differentiation [25, 26].
Pregnancy primes the maternal immune system (both B
and T cells) against paternal human leukocyte antigens of
the fetus [27]. The mechanism of immunological tolerance
to the fetus and placenta has been extensively studied [28].
The fetoprotective role of maternal regulatory T cells
(Tregs) is thought to be crucial [29]. Oestradiol has been
shown to potentiate the suppressive function of human
Tregs by promoting their antigen independent proliferation
[30]. Therefore, pregnancy may be a state of enhanced
immunotolerance and remission of autoimmune disease
may be explained by a ‘‘bystander’’ or ‘‘linked’’ blunting of
lymphocyte activation of pathological importance.
Based on these considerations, in the present study we
compared the size of activated subsets within various
lymphocyte populations, T cells (CD4 and CD8), NK T
cells, B lymphocytes and NK cells in pregnant and age-
matched non-pregnant women suffering from asthma of
similar degree. Age-matched healthy pregnant and healthy
non-pregnant women were included as control subjects.
Methods
Subjects
This study included 21 asthmatic pregnant women in their
second and third trimesters of pregnancy (second
trimester: n = 11, third trimester: n = 10) with mean age
of 31.7 ± 1.0 (mean ± SEM) years. They had routine
obstetrical control at the Ist Department of Obstetrics and
Gynecology, Semmelweis University, and were referred
to the Asthma Outpatient Clinic, Department of Pul-
monology, Semmelweis University, if history of asthma
was reported. At the time of examination no asthmatic
patient was experiencing exacerbation. Venous blood was
drawn for routine laboratory tests and also for introduc-
tion into heparinized test tubes for ﬂow cytometric
analysis of lymphocytes, as published earlier [14]. Spi-
rometry, whole body plethysmography and arterialized
capillary blood gas and acid–base were analyzed. Asthma
Control Test was recorded. Patients with clear evidence
of respiratory tract infection (fever, purulent sputum,
positive culture of sputum and need for antibiotic treat-
ment) were excluded.
Three groups of control subjects were included: healthy
pregnant women (n = 13) with mean age of 29.6 ±
1.0 years and similar gestational age (seven women in the
second and six women in the third trimester), healthy non-
pregnant (n = 10) with mean age of 29.7 ± 1.5 years and
asthmatic non-pregnant women (n = 12) with mean age of
31.5 ± 1.5 years. All patients were atopic and non-smok-
ing. Asthmatic non-pregnant women were monitored at the
Asthma Outpatient Clinic, Department of Pulmonology,
Semmelweis University.
Asthmatic pregnant and non-pregnant women had mild
to moderate persistent asthma as deﬁned by the Global
Initiative for Asthma (GINA) [31]. The onset and severity
of asthma, previous results of skin prick tests with inhaled
allergens, anti-asthma medications and changes of asth-
matic symptoms during pregnancy were recorded. None of
them were on systemic steroid 6 weeks prior to the visit or
during pregnancy. Short-, or long-acting b2-agonist and
inhaled steroids had been used as anti-asthma treatments.
At the time of pulmonary examination and blood with-
drawal three patients from the asthmatic non-pregnant
group and 10 women in the asthmatic pregnant group had
not been receiving inhaled steroid.
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Peripheral venous blood was collected by venipuncture,
using the Becton–Dickinson (BD, San Jose, CA, USA)
Vacutainer
 Heparin Tubes. Immunophenotypic analysis
was performed on the day of sample collection. All anti-
bodies used for the characterization of different cell
populations were manufactured by BD Biosciences
Pharmingen. The ‘‘Direct Immunoﬂuorescence Staining of
Cells Using a Lyse/Wash Procedure’’ protocol of BD
Biosciences [32] was used for staining the cell surface
antigens. Before the measurements, cells were ﬁxed by 2%
paraformaldehyde solution (Sigma–Aldrich, St. Louis,
MO, USA). Multicolor staining procedure was used for the
detection of lymphocyte subsets as indicated in Table 1
The percentual ratio of lymphocyte subsets was related to
the lymphocyte gate. The lymphocyte gate was determined
according to the size and granulation by the FS/SS dot plot.
The purity of the gate was detected by CD45/CD14
labeling. The lymphocyte gate was set considering the
amount of CD45
? lymphocytes (more than 95%) and the
ratio of CD45
?/CD14
? monocytes (less than 3%). Isotype
control antibodies were used for the detection of aspeciﬁc
staining.
Measurements were carried out using a FACSCalibur
ﬂow cytometer (BD) on the day of the staining, collecting
2.5 9 10
4–1 9 10
5 cells/tube. CellQuest-Pro Software
(BD) was used for analysis.
The absolute numbers of cells and their subsets in
clinical samples were assessed using dual-platform count-
ing technologies, which couples the percentage of positive
cell subsets counted by ﬂow cytometry and the absolute
cell count measured by automated hematology analyzer
(Cell-Dyne 3200, Abbott) [33].
Statistics
Data are shown as means ± SEM. Statistical analysis was
performedbyANOVAandiftherewassigniﬁcant(p\0.05)
difference among the four groups, the Newman–Keuls mul-
tiple comparison post-hoc test was used for further analysis.
Post-hoc pair-wise comparisons were carried out between
the following groups: 1. asthmatic non-pregnants versus
healthy non-pregnants 2. healthy pregnants versus healthy
non-pregnants 3. asthmatic pregnants versus healthy preg-
nants. The unpaired t test and Fischer’s exact test were used
where indicated. Correlations were analysed by multiple
linear regression.
Results
Clinical data
The mean age of study groups was around 29–32 years,
with no signiﬁcant difference between them (Table 2).
Table 1 Characterization of
circulating lymphocyte
subpopulations by
immunophenotyping
FITC Pe PerCP or Cy-chrome APC
Isotype control Ab Isotype control Ab Isotype control Ab Isotype control Ab
CD25 CD8 CD4 CD3
CD71 CD152 CD19 CD3
CD56 HLA-DR CD16 CD3
CD45 CD14
CD28 CD54 CD4 CD11b
CD28 CD54 CD8 CD11b
Table 2 Age and obstetrical data of subjects (means ± SEM)
Healthy non-pregnant Asthmatic non-pregnant Healthy pregnant Asthmatic pregnant
Number 10 12 13 21
Age (year) 29.0 ± 1.6 31.4 ± 1.7
ns 29.6 ± 1.1
ns 31.7 ± 1.0
ns
BMI (kg/m
2) 20.6 ± 0.44 25.02 ± 1.45
a 24.77 ± 0.55
a 26.0 ± 1.1
a,ns
Gestational age (week) at examination – – 26.8 ± 2.0 26.4 ± 1.7
ns
At delivery – – 39.1 ± 0.3 38.9 ± 0.3
ns
Mean birth weight (g) – – 3,332 ± 93.1 3,224 ± 145.5
b
Sex of newborns (female/male) – – 5/8 8/13
BMI body mass index
a p\0.05 vs. the healthy non-pregnant group
b p\0.05 vs. the healthy pregnant group, ns not signiﬁcant vs. the appropriate healthy group
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asthmatic than healthy non-pregnants (Table 2). No such
difference was observed between the two pregnant groups.
The mean gestational age at pulmonary examination was
about 26th week in both healthy and asthmatic pregnant
women. The mean gestational age at delivery was also
similar (Table 2). Birth weight of newborns of asthmatic
mothers was slightly lower as compared to healthy controls
(p\0.05). Peak expiratory ﬂow was signiﬁcantly reduced
in both asthmatic groups (non-pregnant and pregnant) rel-
ative to predicted control values (p\0.05, Table 3). Non-
pregnant and pregnant asthmatics had similar degrees of
airway obstruction and hypoxaemia (Table 3). Hypocapnia
of both non-pregnant and pregnant asthmatics was mild.
pCO2 of asthmatic pregnants was signiﬁcantly (p\0.001)
lower than in non-pregnants, but within the reference range
of pCO2 of healthy pregnants (28–32 mmHg, [34]).
Impaired maternal airway function and reduced birth
weights showed no statistically signiﬁcant relationship.
Gender of the newborn had no inﬂuence on any clinical
parameters of asthmatic pregnants. Nine non-pregnant and
11 pregnant asthmatics were treated with inhaled cortico-
steroid (ICS). The daily doses of various anti-asthma
medications used are also shown in Table 3. All asthmatics
were stable, none of them suffered from exacerbation.
Healthy and asthmatic pregnant patients had signiﬁ-
cantly lower red blood cell count compared to healthy and
asthmatic non-pregnants (4.10 ± 0.09 and 4.17 ± 0.11 vs.
4.80 ± 0.09 and 4.63 ± 0.09 T/l, respectively), but all
values were in the appropriate reference ranges [35].
Both, healthy and asthmatic pregnant groups had signiﬁ-
cantly (p\0.01) higher neutrophil counts compared to
appropriate groups of non-pregnants (7.47 ± 0.47 and
7.86 ± 0.60 vs. 4.71 ± 0.55 and 4.37 ± 0.39 G/l, respec-
tively). Eosinophil numbers were slightly but not statistically
elevated in both, the non-pregnant and pregnant asthmatic
groups.
Lymphocyte activation
Non-pregnant asthmatics versus non-pregnant healthy
subjects
Nearly all measured subpopulations of lymphocytes within
T (CD3
?) and B (CD19
?) cells had greater activated
fractions in asthmatic than non-pregnant healthy subjects
(Tables 4, 5). Larger fractions of CD25
? and CD95
? T
cells, and larger CD25
?, CD28
? or CD54
? fractions of
CD4
? cells were observed. The number of CD54
? and
CD11b
? subsets within CD8
? cells and that of activated,
CD71
? B cells also increased (Table 5). The size of the
NK (CD3
-CD16
?CD56
?) pool remained unchanged, but
the number of NK T (CD3
?CD16
?CD56
?) cells were
increased in non-pregnant asthmatic versus healthy indi-
viduals (Table 4). These results indicated activation of T
and B lymphocytes, as well as an increased pool of NK T
cells in peripheral blood of patients with mild to moderate
persistent asthma.
Healthy pregnants versus healthy non-pregnants
According to several markers tested, normal pregnancy
was a state of widespread lymphocyte activation (Tables 4,
5). The number of CD25
? and CD95
? T cells, CD25
? or
Table 3 Clinical data of asthmatic patients (non-pregnant and pregnant; means ± SEM, where appropriate)
Asthmatic non-pregnant (12) Asthmatic pregnant (21)
Distribution of asthma severity (GINA II/III) 8/4 17/6
ns
PEF (% of predicted) 72.08 ± 5.41* 72.5 ± 3.16*
FEV1 (% of predicted) 86.00 ± 5.59 87.62 ± 3.24
Raw (kPa 9 s/l) 0.34 ± 0.06
$ 0.27 ± 0.03
$
pO2 (mmHg) 84.03 ± 3.4* 88.35 ± 2.12*
pCO2 (mmHg) 35.47 ± 0.75* 30.93 ± 0.49*,
}
pH 7.52 ± 0.01
$ 7.51 ± 0.01
$
Number of patients on inhaled corticosteroid (ICS) 9 11
ns
Number of patients on inhaled long-acting b2-agonist (LABA) 4 4
ns
Daily dose of inhaled short-acting b2-agonist (puffs) 2 (0, 4)
a 2 (0, 4)
a
Daily dose of inhaled formoterol (lg) 11.25 10.13
ns
Daily dose of inhaled corticosteroid (beclomethasone equivalent lg) 587 ± 74 781 ± 120
ns
GINA global initiative for asthma, PEF peak expiratory ﬂow; Raw-airway resistance; pO2 partial pressure of oxygen in arterialized capillary
blood; pCO2 partial pressure of carbon-dioxide in arterialized capillary blood; FEV1-forced expiratory volume in one-second, ns non signiﬁcant
vs. non-pregnant astmatics; *less or
$more than the healthy age matched population mean ± 2 9 SD;
}signiﬁcant (p\0.001) vs. asthmatic non-
pregnant
a Median, smallest, largest. No signiﬁcant differences among the two asthmatic groups except for pCO2
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? CD4
? cells, CD54
? or CD11b
? CD8
? cells, NK
T cells and CD71
? B cells were all signiﬁcantly higher in
healthy pregnant compared to healthy non-pregnant women.
Direct correlation (p\0.01) was revealed between the
CD95
? T cell count and birth weight.
Pregnant asthmatics versus other groups
In pregnant asthmatic patients, the size of activated pools
of most lymphocyte subsets remained unchanged relative
to those in healthy pregnants (Tables 4, 5). The CD71
? B
cell population was, however, smaller in asthmatic versus
healthy pregnants.
Multiple linear regression analyses were performed
betweenthe sizes ofvariousactivatedlymphocytepools and
airway parameters or birth weights. Higher number of cir-
culating CD3
?CD8
?, CD3
?HLADR
?, and CD8
?CD28
?
lymphocytes displayed indirect linear correlations with
FEV1; higher CD3
?HLADR
? and CD8
?CD28
? numbers
showed direct linear correlation with Raw; and higher
CD8
?CD28
? cell counts presented indirect linear correla-
tion with pO2. It became clear, however, that several linear
regressions reached statistical signiﬁcance because of 2 (out
of the 21) pregnant asthmatics who demonstrated the most
severe clinical abnormalities as well as most activated
lymphocytes. One of these 2 pregnant asthmatics had the
most severe airway obstruction (FEV1: 38%), the largest
pools of CD3
?CD8
?, CD3
?HLADR
?, CD8
?CD28
? cells
and gave birth (at term) to her newborn with smaller
than average body weight (2650 g). The other asthmatic
pregnant patient delivered the most growth retarded
(1,690 g) newborn (35th week of gestation) and also had
very high numbers of activated lymphocytes (CD3
?CD25
?,
CD4
?CD25
?, CD8
?CD25
?), meanwhile demonstrating
smaller than average FEV1. Leaving out the two highest
lymphocyte and lowest FEV1 values belonging to those
asthmatic mothers who gave birth to the smallest newborns
led to loss of statistical signiﬁcance. The same applied to the
Table 4 Major lymphocyte sub-populations in peripheral blood of non-pregnant healthy and asthmatic subjects, and healthy and asthmatic
pregnants (total numbers of cells/ll blood, means ± SEM)
Lymphocyte
subset
Immuno-phenotype Healthy non-pregnant
(n = 10)
Asthmatic non-pregnant
(n = 12)
Healthy pregnant
(n = 13)
Asthmatic pregnant
(n = 21)
T cells CD3
? 1,325 ± 118.1 1,586 ± 134.8 1,405 ± 60.3 1,256 ± 61.9
}
T-helper cells CD3
?CD4
? 777.2 ± 92.4 947.3 ± 94.4 764.7 ± 35.0 771.9 ± 42.1
T-cytotoxic cells CD3
?CD8
? 453.1 ± 43.3 554.9 ± 62.6 557.8 ± 39.1 435.3 ± 28.0
NK T cells CD3
?CD16
?CD56
? 117.5 ± 19.1 238.1 ± 27.0** 200.6 ± 20.4* 178.2 ± 16.2
B cells CD19
? 128.6 ± 10.5 183.1 ± 22.9 163.1 ± 13.3 174.3 ± 14.4
NK cells CD3
-CD16
?CD56
? 256.2 ± 56.1 296.1 ± 73.9 233.1 ± 49.1 300.8 ± 45.1
Statistical analysis: ANOVA and Newman–Keuls comparison post-hoc test were applied if possible.
}p\0.05 vs. asthmatic non-pregnant;
*p\0.05; **p\0.01 vs. healthy non-pregnant
Table 5 Distribution of activated lymphocyte sub-populations in peripheral blood of non-pregnant healthy and asthmatic subjects and healthy,
or asthmatic pregnants (total numbers of cells/ll blood; means ± SEM)
Immuno-phenotype Healthy non-pregnant
(n = 10)
Asthmatic non-pregnant
(n = 12)
Healthy pregnant
(n = 13)
Asthmatic pregnant
(n = 21)
CD3
?CD25
? 155.0 ± 23.6 288.8 ± 29.1** 240.4 ± 19.3* 244.7 ± 23.3
CD3
?CD95
? 344.5 ± 39.3 708.7 ± 72.5** 573.7 ± 72.8* 580.5 ± 54.7
CD3
?HLADR
? 26.77 ± 6.8 33.11 ± 6.5 35.56 ± 7.7 23.43 ± 2.2
CD4
?CD25
? 126.1 ± 20.3 245.0 ± 27.6* 207.2 ± 16.3* 222.0 ± 22.3
CD4
?CD28
? 619.94 ± 109.2 972.9 ± 120.7* 736.0 ± 30.3 703.6 ± 45.9
CD4
?CD54
? 73.9 ± 13.9 193.1 ± 32.8* 126.2 ± 18.3 192.6 ± 26.8
CD4
?CD11b
? 28.5 ± 5.2 53.58 ± 13.3 91.78 ± 20.9* 51.57 ± 10.9
CD8
?CD25
? 22.7 ± 3.6 45.08 ± 8.4 35.44 ± 9.3 30.10 ± 4.2
CD8
?CD28
? 295.7 ± 34.9 368.7 ± 41.0 345.7 ± 26.8 282.8 ± 20.5
CD8
?CD54
? 74.02 ± 13.87 193.2 ± 32.8* 278.6 ± 28.9** 274.2 ± 30.8
CD8
?CD11b
? 116.1 ± 15.2 215.2 ± 25.2* 249.2 ± 36.0* 220.0 ± 22.8
CD19
?CD71
? 44.2 ± 6.9 100.5 ± 22.1* 105.6 ± 12.9* 55.0 ± 9.0
$
*p\0.05; **p\0.01 vs. healthy non-pregnants;
$p\0.05 vs. healthy pregnants
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?CD28
?,CD8
?CD25
?,or
CD4
?CD25
?cellularpoolsandbirthweights.TheBMIwas
not correlated with the size of any lymphocyte subsets,
FEV1,R a w ,p O 2 or birth weight.
Discussion
The course of several immunological diseases improves
[15–17] during pregnancy and in at least one-third of
asthmatic women asthma symptoms become temporarily
reduced during pregnancy [13]. One possible mechanism of
these phenomena is pregnancy-induced immunotolerance.
Maternal immunotolerance is necessary for mammalian
reproduction. HLA-G expressed on the syntitiotrophoblast
binds NK cells and inhibits killing; placental indoleamine
2,3-dioxygenase consumes tryptophan in the vicinity of
placental effector T cells, which become paralysed due to
tryptophan deﬁciency; and the placenta synthesizes pro-
gesterone and placental growth hormone, both of which
inhibit immune response [28]. In addition, apoptotic T cells
are detected in human decidua; the speciﬁc ligand of CD95
is expressed on trophoblasts and there is CD95 on many
activated maternal T cells, which enter into contact with the
conceptus. The present study conﬁrmed the existence of a
direct, quantitative relationship between the number of pre-
apoptotic (CD95
?) T cells and birth weight in healthy, but
not in asthmatic, pregnants.
According to Aluvihare et al. [29], regulatory T cells
mediate maternal tolerance to the fetus. Foxp3 mRNA
content is 1,000-fold higher in the pregnant than in the non-
pregnant uterine wall [29], which probably reﬂects accu-
mulation of Treg cells in the decidua. Absence of this
lymphocyte subgroup causes rejection of the fetus [29].
During physiologic pregnancy, estradiol boosts the sup-
pressive function of Treg cells by promoting their antigen
independent proliferation [30]. Immunologic tolerance
mediated by Treg cells during pregnancy can be antigen
independent [29] and during pregnancy tolerance is not
only expressed towards fetal (paternal) antigens, but auto-
antigens as well [15, 36]. The Treg subpopulation of
lymphocytes is spread all over the maternal organism,
peripheral blood [37, 38], spleen and thymus [39]. Immu-
nological tolerance during pregnancy is also observed
remote from the intrauterine environment [40]. Accord-
ingly, splenocytes of primiparous mice proliferate follow-
ing exposure to fetal cells, whereas those of virgin mice do
not [41]. Anti-idiotypic (anti-paternal HLA speciﬁc T cell
receptor) antibodies can be recovered from circulating
plasma of previously pregnant women [42]. Based on these
considerations we raised the hypothesis that pregnancy
might reduce allergic airway inﬂammation via pregnancy-
induced, bystander, or linked immunologic tolerance. The
present ﬁndings supported this hypothesis, because in
almost no pregnant mild or moderate, persistant asthmatic
patients was there any additive activation of T or B cells, or
culminating numbers of NK T lymphocytes.
The interaction of asthma and pregnancy may depend
on severity of asthma or other maternal complications
during pregnancy. There was an association between
obesity and asthma. Asthma is more prevalent among
obese subjects [43], and obesity is more frequently
associated with a difﬁcult-to-control phenotype of asthma
[44]. Within mild-to-moderate persistent asthmatics,
however, increased BMI is not associated with worse
clinical symptoms [45] .A c c o r d i n gt os e c o n d a r ya n a l y s i s
of the prospective cohort in the Asthma During Preg-
nancy Study, obesity is associated with an increased risk
of exacerbations during pregnancy [46]. In our present
study the body mass index was also signiﬁcantly higher in
non-pregnant asthmatic versus healthy women, but no
major difference was found between the two pregnant
groups. All our patients suffered from mild-to-moderate
persistent asthma. In accordance with previous publica-
tions [45, 46] in these patients BMI and lung function
were not related. Within the pregnant asthmatics group,
those two patients who had the most severe airway
obstruction were also outlyers regarding the body weight
of newborns and pools of activated lymphocytes. In our
previous study [14] we had three such patients suffering
from severe asthma and preeclampsia and also presenting
large fractions of lymphocytes synthesizing interferon-c.
They also delivered at term, but their newborns were very
small (1,000–1,500 g). It remains a question whether
major immunological activation in more severe asthma
during pregnancy may cause severe fetal growth retar-
dation, or whether other maternal complications which
are responsible for severe retardation of fetal growth (e.g.
chorioamnionitis) also worsen asthma.
In conclusion, the analysed lymphocyte subpopulations
were activated both in healthy pregnancy and asthma. In
asthmatic pregnants with mild or moderate persistent dis-
ease, however, no additive increase in counts of activated
lymphocytes was observed. This may indicate the existence
of pregnancy-induced moderation of lymphocyte activation
associated with allergic asthma.
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